SoMore trial: Early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC)

MLA

Marie Diaz, et al. SoMore Trial: Early Metabolic Response Assessment of a Sorafenib (SOR) and Capecitabine (CAP) Combination in Chemorefractory Metastatic Colorectal Cancer (MCRC). EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....55ba23a9c0bf7bd83dd3570155a9c3bc&authtype=sso&custid=ns315887. Accessed 4 Mar. 2025.

APA

Marie Diaz, Camilo Garcia, Stéphane Holbrechts, Marc Van den Eynde, Jean-Luc Van Laethem, Patrick Flamen, Gauthier Demolin, Raphaël Maréchal, Alain Hendlisz, Marcus Peeters, Thierry Delaunoit, Am Lie Deleporte, Christian Rolfo, Ghislain Houbiers, Michel Moreau, Bertrand Filleul, Lieveke Ameye, Martine Piccart-Gebhart, Renaud Lhommel, & Marianne Paesmans. (n.d.). SoMore trial: Early metabolic response assessment of a sorafenib (SOR) and capecitabine (CAP) combination in chemorefractory metastatic colorectal cancer (mCRC).

Chicago

Marie Diaz, Camilo Garcia, Stéphane Holbrechts, Marc Van den Eynde, Jean-Luc Van Laethem, Patrick Flamen, Gauthier Demolin, et al. 2025. “SoMore Trial: Early Metabolic Response Assessment of a Sorafenib (SOR) and Capecitabine (CAP) Combination in Chemorefractory Metastatic Colorectal Cancer (MCRC).” Accessed March 4. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....55ba23a9c0bf7bd83dd3570155a9c3bc&authtype=sso&custid=ns315887.